Stock Price Quote

VENUS REMEDIES LTD.

NSE : VENUSREMBSE : 526953ISIN CODE : INE411B01019Industry : Pharmaceuticals & DrugsHouse : Private
BSE384.107.65 (+2.03 %)
PREV CLOSE ( ) 376.45
OPEN PRICE ( ) 383.90
BID PRICE (QTY) 383.15 (1)
OFFER PRICE (QTY) 384.05 (44)
VOLUME 12898
TODAY'S LOW / HIGH ( )375.10 389.80
52 WK LOW / HIGH ( )222 429.6
NSE384.107.45 (+1.98 %)
PREV CLOSE( ) 376.65
OPEN PRICE ( ) 377.50
BID PRICE (QTY) 384.10 (52)
OFFER PRICE (QTY) 384.90 (33)
VOLUME 160497
TODAY'S LOW / HIGH( ) 374.30 389.85
52 WK LOW / HIGH ( )222 430
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1989
Management Info
Pawan Chaudhary - Chairman Pawan Chaudhary - Managing Director
Registered Office

Address S. C. O. 857, C. No. 10,2nd Floor,N A C Manimajra,
Chandigarh,
Chandigarh-160101

Phone 0172-2561244/5577

Email info@venusremedies.com

Website www.venusremedies.com / www.vmrcindia.com

Registrars Details
Link Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE, MCX

NEWS

19Jun Venus Remedies gets oncology tender fr
Venus Remedies has been awarded an oncology tender by the WHO-backed Pan..
19Jun Venus Remedies rises on getting oncolo
Venus Remedies is currently trading at Rs. 377.80, up by 3.05 points or..
14Jun Venus Remedies Achieves Major Milesto
Venus Remedies achieves major milestone with UNICEF by securing the pres..
13Jun Venus Remedies secures award for antib
Venus Remedies has reached a significant milestone by securing the prest..
13Jun Venus Remedies informs about updates
Venus Remedies has informed that the Company has proudly reached a signi..

Financials

in Millions
QTR Mar 24 ANNUAL 24
Net Profit125.1305
Gross Profit 194.7 466.5
Operating Profit 251.9722
Net Sales 1751.65752.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE)
peergroup  932.30 (6.44%)
M.Cap ( in Cr)405.09
Neuland Laboratories (BSE)
peergroup  6544.85 (0.82%)
M.Cap ( in Cr)8420.45
Divi's Lab (BSE)
peergroup  4521.00 (0.97%)
M.Cap ( in Cr)118717.55
Shilpa Medicare (BSE)
peergroup  569.10 (7.85%)
M.Cap ( in Cr)5518.83
Solara Active Pharma (BSE)
peergroup  446.80 (6.46%)
M.Cap ( in Cr)2121.78

Shareholding Pattern

NON-INSTITUTION 56.76%
PROMOTERS 41.76%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Venus Remedies Ltd.

Venus Remedies Ltd. was incorporated in the year 1989. Its today's share price is 384.1. Its current market capitalisation stands at Rs 505.07 Cr. In the latest quarter, company has reported Gross Sales of Rs. 5376.62 Cr and Total Income of Rs.5478.36 Cr. The company's management includes Neha Kodan, Akshansh Chaudhary, Ashutosh Jain, NPS Monga, Savita Gupta, Navdeep Sud, S K Chadha, Gilbert Wenzel, Peeyush Jain, Manu Chaudhary, Pawan Chaudhary, Pawan Chaudhary.

It is listed on the BSE with a BSE Code of 526953 , NSE with an NSE Symbol of VENUSREM and ISIN of INE411B01019. It's Registered office is at S. C. O. 857, C. No. 10,2nd Floor,N A C ManimajraChandigarh-160101, Chandigarh. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are JK Jain & Associates, Prem Garg & Associates, Vinod Kumar & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.